期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 16, 期 2, 页码 147-164出版社
TAYLOR & FRANCIS AS
DOI: 10.1586/14737159.2016.1123095
关键词
Circulating tumor cells; CTC; CTCs; CTC frequency; diagnostic leukapheresis; DLA; liquid biopsy; single cell analysis; CTC profiling; CTC characterization
类别
资金
- DFG [STO464/2-2]
- Deutsche Krebshilfe [109600/110429]
- Krebsstiftung North Rhine-Westphalia
- Krebsgesellschaft North Rhine-Westphalia
- Bayer Healthcare
- Janssen Diagnostics
- EU FP7 [HEALTH.2012.1.2-1, 305341]
- Cancer-ID project - Innovative Medicines Joint Undertaking (IMI JU)
Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer. Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy to gain molecular information for rational therapeutic decision-making. The advancements in molecular analyses of CTCs down to the single-cell level have been significant in recent years and some applications are ready to be used in clinical studies. As discussed in this review, a major challenge for translating such molecular CTC-based assays into the clinic is the extremely low frequency of CTCs and the associated problems of their reliable detection and isolation. A potential solution to overcome the low CTC frequency is the recently introduced diagnostic leukapheresis that permits screening of liters of blood. Discussed here are the challenges as well as the current efforts implementing this method into clinical workflows to realize more reliable liquid biopsies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据